[Prescribed
dose] [100ml] [ 15 minutes]
Examples:
[500 mg]
[100ml] [15 minutes]
[1000 mg ] [100ml] [15 minutes]
[1500 mg ] [100ml] [15 minutes]
(Product with particulate matter or discoloration should not be used.)
Indications: KEPPRA injection is indicated as adjunctive therapy in the
treatment of partial onset seizures in ADULTS with epilepsy.
KEPPRA injection is an alternative for patients when oral administration is
temporarily not feasible.
(Safety and effectiveness of KEPPRA injection in patients below the age of
16 years have not been established.)
Dosage: KEPPRA injection is for intravenous use only and must be diluted prior to
administration. Treatment should be initiated with a daily dose of 1000 mg/day, given as
twice-daily dosing (500 mg BID). Additional dosing increments may be given
(1000 mg/day additional every 2 weeks) to a maximum recommended daily
dose of 3000 mg. Doses greater than 3000 mg/day have been used in open label
studies with KEPPRA tablets for periods of 6 months and longer. There
is no evidence that doses greater than 3000 mg/day confer additional benefit. Note:
dosage adjustments are necessary in patients with
impaired renal function.
Impaired Renal Function:
First estimate the patient's creatinine clearance
(ml/min):
Cockcroft and Gault equation: |
[140 - age (years)] x weight (kg)
--------------------------------------------------
(x 0.85 for females)
(72 x Serum
creatinine (mg/dl)) |
| CRCL
(ml/min) |
Dosage |
Frequency |
| >
80 ml/min |
500-1500
mg |
q12h |
| 50
- 80 |
500-1000
mg |
q12h |
| 30
- 50 |
250-750
mg |
q12h |
| <30 |
250-550
mg |
q12h |
| ESRD
patients on dialysis |
500-1000
mg |
q24h* |
| *Following
dialysis, a 250 to 500mg supplemental dose is
recommended |
Replacement Therapy: When switching from oral KEPPRA, the initial total daily intravenous dosage
of KEPPRA should be equivalent to the total daily dosage and frequency of
oral KEPPRA . Any unused portion of the KEPPRA injection vial contents should be
discarded.
|
